O	0	10	Expression	Expression	NN	B-NP
O	11	13	of	of	IN	B-PP
O	14	17	DCC	DCC	NN	B-NP
O	18	21	and	and	CC	I-NP
O	22	28	netrin	netrin	NN	I-NP
O	28	29	-	-	HYPH	B-NP
O	29	30	1	1	CD	I-NP
O	31	33	in	in	IN	B-PP
O	34	40	normal	normal	JJ	B-NP
O	41	46	human	human	JJ	I-NP
B-Multi-tissue_structure	47	58	endometrium	endometrium	NN	I-NP
O	59	62	and	and	CC	O
O	63	66	its	its	PRP$	B-NP
O	67	78	implication	implication	NN	I-NP
O	79	81	in	in	IN	B-PP
B-Multi-tissue_structure	82	93	endometrial	endometrial	JJ	B-NP
O	94	108	carcinogenesis	carcinogenesis	NN	I-NP
O	108	109	.	.	.	O

O	111	120	OBJECTIVE	OBJECTIVE	NN	B-NP
O	120	121	:	:	:	O
O	122	130	Although	Although	IN	B-SBAR
O	131	134	DCC	DCC	NN	B-NP
O	135	138	has	have	VBZ	B-VP
O	139	143	been	be	VBN	I-VP
O	144	154	considered	consider	VBN	I-VP
O	155	157	as	as	IN	B-PP
O	158	159	a	a	DT	B-NP
O	160	169	candidate	candidate	NN	I-NP
B-Cancer	170	175	tumor	tumor	NN	I-NP
O	176	186	suppressor	suppressor	NN	I-NP
O	186	187	,	,	,	O
O	188	191	the	the	DT	B-NP
O	192	197	roles	role	NNS	I-NP
O	198	200	it	it	PRP	B-NP
O	201	206	plays	play	VBZ	B-VP
O	207	209	in	in	IN	B-PP
O	210	213	the	the	DT	B-NP
B-Multi-tissue_structure	214	221	uterine	uterine	JJ	I-NP
I-Multi-tissue_structure	222	233	endometrium	endometrium	NN	I-NP
O	234	237	and	and	CC	B-PP
O	238	240	in	in	IN	B-PP
O	241	244	the	the	DT	B-NP
O	245	257	carcinogenic	carcinogenic	JJ	I-NP
O	258	265	process	process	NN	I-NP
O	266	273	remains	remain	VBZ	B-VP
O	274	281	unclear	unclear	JJ	B-ADJP
O	281	282	.	.	.	O

O	283	285	To	To	TO	B-VP
O	286	292	define	define	VB	I-VP
O	293	298	these	these	DT	B-NP
O	299	304	roles	role	NNS	I-NP
O	305	309	more	more	RBR	B-ADVP
O	310	317	clearly	clearly	RB	I-ADVP
O	317	318	,	,	,	O
O	319	321	we	we	PRP	B-NP
O	322	330	examined	examine	VBD	B-VP
O	331	334	the	the	DT	B-NP
O	335	345	expression	expression	NN	I-NP
O	346	348	of	of	IN	B-PP
O	349	352	DCC	DCC	NN	B-NP
O	353	356	and	and	CC	O
O	357	360	its	its	PRP$	B-NP
O	361	367	ligand	ligand	NN	I-NP
O	367	368	,	,	,	O
O	369	375	netrin	netrin	NN	B-NP
O	375	376	-	-	HYPH	B-NP
O	376	377	1	1	CD	I-NP
O	377	378	,	,	,	O
O	379	381	in	in	IN	B-PP
O	382	385	the	the	DT	B-NP
O	386	392	normal	normal	JJ	I-NP
B-Multi-tissue_structure	393	404	endometrium	endometrium	NN	I-NP
O	405	408	and	and	CC	B-PP
O	409	411	in	in	IN	B-PP
B-Cancer	412	423	endometrial	endometrial	JJ	B-NP
I-Cancer	424	430	cancer	cancer	NN	I-NP
O	430	431	.	.	.	O

O	432	439	METHODS	METHODS	NNS	B-NP
O	439	440	:	:	:	O
O	441	444	The	The	DT	B-NP
O	445	455	expression	expression	NN	I-NP
O	456	458	of	of	IN	B-PP
O	459	462	DCC	DCC	NN	B-NP
O	463	466	and	and	CC	I-NP
O	467	473	netrin	netrin	NN	I-NP
O	473	474	-	-	HYPH	B-NP
O	474	475	1	1	CD	I-NP
O	476	478	in	in	IN	B-PP
O	479	485	normal	normal	JJ	B-NP
B-Multi-tissue_structure	486	497	endometrial	endometrial	JJ	I-NP
I-Multi-tissue_structure	498	504	glands	gland	NNS	I-NP
O	505	508	and	and	CC	B-PP
O	509	511	in	in	IN	B-PP
B-Cell	512	518	cancer	cancer	NN	B-NP
I-Cell	519	523	cell	cell	NN	I-NP
I-Cell	524	529	lines	line	NNS	I-NP
O	530	533	was	be	VBD	B-VP
O	534	542	examined	examine	VBN	I-VP
O	543	545	by	by	IN	B-PP
O	546	548	RT	RT	NN	B-NP
O	548	549	-	-	HYPH	B-NP
O	549	552	PCR	PCR	NN	I-NP
O	553	556	and	and	CC	I-NP
O	557	577	immunohistochemistry	immunohistochemistry	NN	I-NP
O	577	578	.	.	.	O

O	579	582	The	The	DT	B-NP
O	583	590	effects	effect	NNS	I-NP
O	591	593	of	of	IN	B-PP
O	594	603	exogenous	exogenous	JJ	B-NP
O	604	607	DCC	DCC	NN	I-NP
O	608	611	and	and	CC	I-NP
O	612	618	netrin	netrin	NN	I-NP
O	618	619	-	-	HYPH	B-NP
O	619	620	1	1	CD	I-NP
O	621	631	expression	expression	NN	I-NP
O	632	636	were	be	VBD	B-VP
O	637	645	observed	observe	VBN	I-VP
O	646	654	together	together	RB	B-ADVP
O	655	659	with	with	IN	B-PP
O	660	663	the	the	DT	B-NP
O	664	674	respective	respective	JJ	I-NP
O	675	685	expression	expression	NN	I-NP
O	686	692	vector	vector	NN	I-NP
O	693	705	transfection	transfection	NN	I-NP
O	705	706	.	.	.	O

O	707	714	RESULTS	RESULTS	NNS	B-NP
O	714	715	:	:	:	O
B-Multi-tissue_structure	716	727	Endometrial	Endometrial	JJ	B-NP
I-Multi-tissue_structure	728	734	glands	gland	NNS	I-NP
O	735	737	in	in	IN	B-PP
O	738	741	the	the	DT	B-NP
O	742	755	proliferative	proliferative	JJ	I-NP
O	756	759	and	and	CC	I-NP
O	760	765	early	early	JJ	I-NP
O	766	775	secretory	secretory	JJ	I-NP
O	776	781	phase	phase	NN	I-NP
O	782	791	expressed	express	VBD	B-VP
O	792	796	both	both	CC	O
O	797	800	DCC	DCC	NN	B-NP
O	801	804	and	and	CC	I-NP
O	805	811	netrin	netrin	NN	I-NP
O	811	812	-	-	HYPH	B-NP
O	812	813	1	1	CD	I-NP
O	813	814	,	,	,	O
O	815	818	but	but	CC	O
B-Multi-tissue_structure	819	825	glands	gland	NNS	B-NP
O	826	828	in	in	IN	B-PP
O	829	832	the	the	DT	B-NP
O	833	837	late	late	JJ	I-NP
O	837	838	-	-	HYPH	I-NP
O	838	847	secretory	secretory	JJ	I-NP
O	848	853	phase	phase	NN	I-NP
O	854	860	tended	tend	VBD	B-VP
O	861	863	to	to	TO	B-PP
O	864	871	silence	silence	NN	B-NP
O	872	875	DCC	DCC	NN	I-NP
O	876	886	expression	expression	NN	I-NP
O	886	887	.	.	.	O

O	888	890	In	In	IN	B-PP
O	891	899	addition	addition	NN	B-NP
O	899	900	,	,	,	O
O	901	904	all	all	DT	B-NP
O	905	907	of	of	IN	B-PP
O	908	911	the	the	DT	B-NP
B-Cell	912	923	endometrial	endometrial	JJ	I-NP
I-Cell	924	930	cancer	cancer	NN	I-NP
I-Cell	931	935	cell	cell	NN	I-NP
I-Cell	936	941	lines	line	NNS	I-NP
O	942	946	lost	lose	VBD	B-VP
O	947	953	normal	normal	JJ	B-NP
O	954	957	DCC	DCC	NN	I-NP
O	958	968	expression	expression	NN	I-NP
O	968	969	.	.	.	O

O	970	978	Restored	Restore	VBN	B-NP
O	979	982	DCC	DCC	NN	I-NP
O	983	993	expression	expression	NN	I-NP
O	994	996	in	in	IN	B-PP
O	997	1000	the	the	DT	B-NP
B-Cell	1001	1007	cancer	cancer	NN	I-NP
I-Cell	1008	1012	cell	cell	NN	I-NP
I-Cell	1013	1018	lines	line	NNS	I-NP
O	1019	1021	in	in	IN	B-PP
O	1022	1025	the	the	DT	B-NP
O	1026	1033	absence	absence	NN	I-NP
O	1034	1036	of	of	IN	B-PP
O	1037	1043	netrin	netrin	NN	B-NP
O	1043	1044	-	-	HYPH	B-NP
O	1044	1045	1	1	CD	I-NP
O	1046	1053	induced	induce	VBN	I-NP
O	1054	1063	apoptosis	apoptosis	NN	I-NP
O	1063	1064	.	.	.	O

O	1065	1072	However	However	RB	B-ADVP
O	1072	1073	,	,	,	O
O	1074	1076	no	no	DT	B-NP
O	1077	1084	changes	change	NNS	I-NP
O	1085	1089	were	be	VBD	B-VP
O	1090	1098	observed	observe	VBN	I-VP
O	1099	1101	in	in	IN	B-PP
O	1102	1105	the	the	DT	B-NP
O	1106	1114	presence	presence	NN	I-NP
O	1115	1117	of	of	IN	B-PP
O	1118	1124	netrin	netrin	NN	B-NP
O	1124	1125	-	-	HYPH	B-NP
O	1125	1126	1	1	CD	I-NP
O	1126	1127	.	.	.	O

O	1128	1138	CONCLUSION	CONCLUSION	NN	B-NP
O	1138	1139	:	:	:	O
O	1140	1143	Our	Our	PRP$	B-NP
O	1144	1156	observations	observation	NNS	I-NP
O	1157	1164	suggest	suggest	VBP	B-VP
O	1165	1169	that	that	IN	B-SBAR
O	1170	1173	DCC	DCC	NN	B-NP
O	1173	1174	/	/	SYM	B-NP
O	1174	1180	netrin	netrin	NN	I-NP
O	1180	1181	-	-	HYPH	B-NP
O	1181	1182	1	1	CD	I-NP
O	1183	1192	signaling	signaling	NN	I-NP
O	1193	1196	may	may	MD	B-VP
O	1197	1203	commit	commit	VB	I-VP
B-Cell	1204	1209	cells	cell	NNS	B-NP
O	1210	1212	to	to	TO	B-PP
O	1213	1216	the	the	DT	B-NP
O	1217	1227	transition	transition	NN	I-NP
O	1228	1230	of	of	IN	B-PP
B-Multi-tissue_structure	1231	1242	endometrial	endometrial	JJ	B-NP
I-Multi-tissue_structure	1243	1248	gland	gland	NN	I-NP
O	1249	1261	architecture	architecture	NN	I-NP
O	1262	1264	or	or	CC	I-NP
O	1265	1273	function	function	NN	I-NP
O	1274	1278	from	from	IN	B-PP
O	1279	1280	a	a	DT	B-NP
O	1281	1294	proliferating	proliferate	VBG	I-NP
O	1295	1297	to	to	TO	B-PP
O	1298	1299	a	a	DT	B-NP
O	1300	1309	secretory	secretory	JJ	I-NP
O	1310	1315	phase	phase	NN	I-NP
O	1315	1316	.	.	.	O

O	1317	1319	In	In	IN	B-PP
O	1320	1328	addition	addition	NN	B-NP
O	1328	1329	,	,	,	O
O	1330	1333	the	the	DT	B-NP
O	1334	1343	silencing	silencing	NN	I-NP
O	1344	1346	of	of	IN	B-PP
O	1347	1350	DCC	DCC	NN	B-NP
O	1351	1361	expression	expression	NN	I-NP
O	1362	1365	may	may	MD	B-VP
O	1366	1376	contribute	contribute	VB	I-VP
O	1377	1379	to	to	TO	B-PP
O	1380	1383	the	the	DT	B-NP
O	1384	1390	escape	escape	NN	I-NP
O	1391	1393	of	of	IN	B-PP
B-Cell	1394	1405	endometrial	endometrial	JJ	B-NP
I-Cell	1406	1412	cancer	cancer	NN	I-NP
I-Cell	1413	1418	cells	cell	NNS	I-NP
O	1419	1423	from	from	IN	B-PP
O	1424	1425	a	a	DT	B-NP
O	1426	1429	DCC	DCC	NN	I-NP
O	1429	1430	-	-	HYPH	B-VP
O	1430	1439	regulated	regulate	VBN	B-NP
O	1440	1449	apoptotic	apoptotic	JJ	I-NP
O	1450	1457	program	program	NN	I-NP
O	1457	1458	,	,	,	O
O	1459	1466	thereby	thereby	RB	B-VP
O	1467	1476	promoting	promote	VBG	I-VP
O	1477	1486	malignant	malignant	JJ	B-NP
O	1487	1497	phenotypes	phenotype	NNS	I-NP
O	1497	1498	.	.	.	O

